Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coya Therapeutics (COYA) Cash from Operations (2022 - 2025)

Coya Therapeutics' Cash from Operations history spans 4 years, with the latest figure at 1130603.0 for Q3 2025.

  • For Q3 2025, Cash from Operations rose 79.3% year-over-year to 1130603.0; the TTM value through Sep 2025 reached 12141941.0, down 19.98%, while the annual FY2024 figure was 10288822.0, 8.04% up from the prior year.
  • Cash from Operations for Q3 2025 was 1130603.0 at Coya Therapeutics, up from 5773296.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 2145874.0 in Q1 2024 and bottomed at 5773296.0 in Q2 2025.
  • The 4-year median for Cash from Operations is 2241080.0 (2023), against an average of 2563277.4.
  • The largest annual shift saw Cash from Operations soared 155.54% in 2024 before it tumbled 231.8% in 2025.
  • A 4-year view of Cash from Operations shows it stood at 2223075.0 in 2022, then dropped by 0.81% to 2241080.0 in 2023, then decreased by 7.53% to 2409767.0 in 2024, then surged by 53.08% to 1130603.0 in 2025.
  • Per Business Quant, the three most recent readings for COYA's Cash from Operations are 1130603.0 (Q3 2025), 5773296.0 (Q2 2025), and 2828275.0 (Q1 2025).